Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Abiraterone Stories

2009-07-10 08:00:00

NEW BRUNSWICK, N.J., July 10 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Cougar Biotechnology, Inc., a development stage biopharmaceutical company with a specific focus on oncology. Johnson & Johnson's tender offer for shares of Cougar Biotechnology common stock expired at 5 p.m. Eastern Daylight Time (EDT) yesterday with approximately 20,148,930,000 shares tendered, representing approximately 95.9% of...

2009-05-21 18:06:00

Access to Late-Stage, First-in-Class Prostate Cancer Treatment Strengthens Presence in Oncology NEW BRUNSWICK, N.J., and LOS ANGELES, May 21 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Cougar Biotechnology, Inc. (Nasdaq: CGRB), a development stage biopharmaceutical company with a specific focus on oncology, today announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer. Cougar Biotechnology,...

2008-10-23 09:00:38

Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics." The Symposium is currently taking place in Geneva, Switzerland. The Phase II clinical trial of CB7630 (COU-AA-002) is being conducted at the University of California, San Francisco Comprehensive Cancer Center with...

2008-10-17 09:00:06

Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the Prostate Cancer Foundation Scientific Retreat. The Prostate Cancer Foundation Scientific Retreat is currently taking place in Lake Tahoe, Nevada. The clinical trial of CB7630 was conducted at the University of Texas M.D. Anderson Cancer Center in order to investigate associations between...

2008-07-28 18:00:17

SCIENTISTS are hailing a new drug to treat aggressive prostate cancer as potentially the most significant advance in the field for 70 years. Abiraterone could treat up to 80% of patients with a deadly form of the disease resistant to currently available chemotherapy, they said. The drug works by blocking the hormones which fuel the cancer. The Institute of Cancer Research hopes a simple pill form will be available in two to three years. An advanced clinical trial involving 1,200...

2008-07-24 00:00:18

By Phil Skelton Health reporter Prostate cancer patients in Gloucestershire have welcomed news of a new drug to treat an aggressive form of the disease. Abiraterone has been developed to fight prostate cancer, which kills 9,000 men in England and Wales every year, according to the NHS. Preliminary trials have shown that the drug can reverse even the most aggressive cancers in up to 80 per cent of cases. It works by blocking the hormones which fuel the cancer. The Institute of Cancer...

2008-07-23 09:00:21

By THOMAS H MAUGH II By Thomas H. Maugh II Los Angeles Times An experimental cancer drug shrank prostate tumors dramatically and more than doubled survival in 70 to 80 percent of patients with aggressive cancers, British researchers reported Tuesday. Although the study published in the Journal of Clinical Oncology covered only 21 patients, the drug is being tested in more than 250 men with what appears to be similar results, experts said. "There is a general sense in the prostate...

2008-07-22 21:00:17

The Phase 1 clinical trial of the drug abiraterone revealed significant tumor shrinkage in men with advanced prostate cancer, researchers in Britain said. The trial also found dramatic falls in the prostate specific antigen levels in the majority of advanced prostate cancer patients who received the drug. The clinical trial was undertaken by London-based The Institute of Cancer Research and The Royal Marsden Hospital. Lead researcher Dr. Johann de Bono said the the new drug...

2008-07-22 06:00:17

By Lyndsay Moss SIMON Bush was first diagnosed with aggressive prostate cancer in 2005. Radiotherapy and hormone therapy initially reduced the severity of the cancer, but tests in August 2006 revealed it had returned with force. Two courses of chemotherapy did not work and Mr Bush, who worked as a banker before he became ill, was referred to take part in the Royal Marsden trial of abiraterone. After just a week, Mr Bush started to see a drop in his PSA levels - a marker for...

2008-07-22 06:00:17

By Lyndsay Moss THOUSANDS of men with prostate cancer could be helped by an "exciting" new drug which potentially represents the biggest step forward in treating the disease for 60 years, researchers revealed yesterday. The drug, abiraterone, could help prolong the lives of up to 10,000 men in the UK each year who suffer the most aggressive - and almost always fatal - form of the disease. The news came after a study found the drug led to tumours shrinking in up to 80 per cent of...